A. Cozzoli

发表

Evaluation of potential synergistic action of a combined treatment with alpha‐methyl‐prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy

B. Nico, V. Longo, A. de Luca, 2011, Neuropathology and applied neurobiology.

Gene expression in mdx mouse muscle in relation to age and exercise: aberrant mechanical-metabolic coupling and implications for pre-clinical studies in Duchenne muscular dystrophy.

A. De Luca, R. Capogrosso, G. Camerino, 2014, Human molecular genetics.

Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.

B. Nico, R. Tamma, A. De Luca, 2016, Pharmacological research.

Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests.

A. De Luca, A. Liantonio, P. Confalonieri, 2009, Journal of applied physiology.

Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle

B. Nico, D. Mangieri, M. Bellis, 2008, Neurobiology of Disease.

Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies.

E. Conte, O. Cappellari, A. De Luca, 2019, Pharmacological research.

Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.

R. Grange, E. Conte, A. De Luca, 2017, Journal of applied physiology.

Effects of Nandrolone in the Counteraction of Skeletal Muscle Atrophy in a Mouse Model of Muscle Disuse: Molecular Biology and Functional Evaluation

E. Conte, A. De Luca, A. Liantonio, 2015, PloS one.

Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy

E. Conte, A. De Luca, A. Liantonio, 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy.

A. De Luca, R. Capogrosso, F. Namour, 2013, Pharmacological research.

Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidase.

E. Conte, A. De Luca, A. Liantonio, 2014, American journal of physiology. Cell physiology.

Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse

K. Davies, S. Wren, A. De Luca, 2011, PloS one.

Effect of a long‐term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy

E. Conte, A. De Luca, R. Capogrosso, 2018, Biochemical pharmacology.

Effects of prednisolone on the dystrophin-associated proteins in the blood–brain barrier and skeletal muscle of dystrophic mdx mice

E. Crivellato, D. Ribatti, B. Nico, 2013, Laboratory Investigation.

Enalapril treatment discloses an early role of angiotensin II in inflammation- and oxidative stress-related muscle damage in dystrophic mdx mice

B. Nico, V. Longo, A. De Luca, 2011, Pharmacological research.

P4.26 Toward the identification of druggable pathways involved in disease-related fatigue in Duchenne muscular dystrophy: In vivo and ex vivo studies in dystrophic mdx mice

R. Grange, R. Capogrosso, A. Luca, 2011, Neuromuscular Disorders.

Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests.

A. De Luca, A. Liantonio, P. Confalonieri, 2009, Journal of applied physiology.